2023
Study Adds Support for Cxbladder Monitor Use in Cancer Surveillance
Pacific Edge today welcomes the release of new research supporting the clinical utility of the company’s genomic biomarker test Cxbladder Monitor in the surveillance for bladder cancer recurrence. [read more]
Pacific Edge to Showcase Leading Biomarker Strategies for the Evaluation and Management of Bladder Cancer at SESAUA
Pacific Edge today announces its key activities and highlights at the 87th Annual AUA Southeastern Section (SESAUA) meeting to be held March 15-18 in Amelia Island, Florida. [read more]
Pacific Edge Rings the Bell on Two Decades as an NZX Listed Company
Pacific Edge today rang the bell on two decades of its shares trading on the NZX Main Board. The ceremony was held at NZX’s offices in Auckland and was attended by Pacific Edge and NZX people, investors, analysts and the media. [read more]
Quarterly Investor Update - Q3 FY23 Test Volumes Rise 36% YOY
Pacific Edge has today released its Third Quarter Shareholder Update showing test volumes processed in its laboratories in the three months to the end of December 2022 increased 36% on the same three-month period a year ago. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.